Market Research Logo

U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021

U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021

The U.S. insomnia market is projected to reach USD 4.24 billion by 2021 from USD 3.38 billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021.
In 2016, the cognitive behavioural therapy for insomnia (CBTI) segment is expected to account for the largest share of the market. The other alternative therapies include exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.

In 2016, the prescription sleep aids segment is expected to account for the largest share of the U.S. insomnia pharmacological treatment market. The launch of Belsomra (Merck & Co., Inc) in 2014 in the U.S. and the anticipated launch of E-2006 (Eisai Co., Ltd.) is expected to drive the growth of the market during the forecast years. However, due to the erosion in branded drugs sales and growing adoption of generics attributed to their low cost and equal efficacy as compared to branded products may hinder the growth of the market. In 2016, the zolpidem segment is expected to account for the largest share of the non-benzodaizepines prescription sleep aids market. However, higher adoption of generic products that are available are cheaper price is negatively affecting the growth of the market.

The over-the-counter sleep aids segment of the U.S. insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period. Reasons attributing to the growth of this market include easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid. In 2016, the antihistamines sleep aids segment is expected to hold the largest share of the over-the-counter sleep aids market, whereas, melatonin is expected to grow at the highest CAGR during the forecast period. Growing awareness about the advantages of melatonin such as least amount of side effects, reduces stress levels, and its growing consumption is driving the growth of this segment in the U.S.

Some of the key players offering insomnia treatment (pharmacological) include Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), and Purdue Pharma L.P. (U.S.).

Research Coverage
The market study covers the U.S. insomnia market, by type of treatment, to estimate the overall market size during 2013 to 2021. This report also covers the drivers, restraints, and opportunities of the market along with the competitive landscape of the U.S. insomnia market players.

Reasons to buy this report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
Market Penetration: Comprehensive information regarding products and services offered by the top players in the U.S. insomnia market
Product Development/Innovation: Detailed insights on research & development activities, and new product launches in the U.S. insomnia market
Market Diversification: Exhaustive information about new products, recent developments, and investments in the U.S. insomnia market
Competitive Assessment: In-depth assessment of strategies, products, and pipeline products of the key players in the U.S. insomnia market


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
      • MARKETS COVERED
      • YEARS CONSIDERED FOR THE STUDY
    • CURRENCY
    • LIMITATIONS
    • KEY STAKEHOLDERS/INFLUENCERS
      • Table KEY STAKEHOLDERS/INFLUENCERS FOR DIAGNOSED INSOMNIA PATIENTS
  • RESEARCH METHODOLOGY
    • MARKET SIZE ESTIMATION - NON-PHARMACOLOGICAL TREATMENTS MARKET
      • MARKET BREAKDOWN AND DATA TRIANGULATION
      • KEY DATA FROM SECONDARY SOURCES
      • KEY DATA FROM PRIMARY SOURCES
    • MARKET SIZE ESTIMATION - PHARMACOLOGICAL TREATMENTS MARKET
      • MARKET SIZE ESTIMATION
      • MARKET BREAKDOWN AND DATA TRIANGULATION
      • KEY DATA FROM PRIMARY & SECONDARY SOURCES
    • RESEARCH ASSUMPTIONS
  • EXECUTIVE SUMMARY
    • INTRODUCTION
  • PREMIUM INSIGHTS
    • PHYSICIANS VIEWS ABOUT COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
      • Table PHYSICIANS VIEWS ABOUT COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
    • AGE-WISE COMMONLY USED/PRESCRIBED TREATMENTS FOR EACH TYPE OF INSOMNIA
      • Table AGE-WISE COMMONLY USED/PRESCRIBED TREATMENTS FOR EACH TYPE OF INSOMNIA
    • LIST OF ONGOING PHASE-III CLINICAL TRAILS FOR INSOMNIA
      • Table LIST OF ONGOING PHASE-III CLINICAL TRAILS FOR INSOMNIA
    • U.S. INSOMNIA MARKET: CONSUMER SELECTION CRITERIA
      • Table INSOMNIA TREATMENT SLECTION CRITERIA: IMPACT ANALYSIS
  • MARKET OVERVIEW
    • DRIVERS
      • RESTRAINTS
      • OPPORTUNITIES
  • NON-PHARMACOLOGICAL TREATMENT MARKET
    • INTRODUCTION
      • COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
      • HYPNOTHERAPY
      • OTHER ALTERNATIVE THERAPIES
    • U.S. INSOMNIA MARKET, BY NON-PHARMACOLOGICAL TREATMENT, THERAPY RECOMMENDATION, 2015 (%)
      • Table U.S. INSOMNIA MARKET, BY NON-PHARMACOLOGICAL TREATMENT (QUALITATIVE ASSESSMENT)
  • PHARMACOLOGICAL TREATMENT MARKET
    • INTRODUCTION
    • U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE , BY TYPE
      • Table U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE , BY TYPE, 2013-2021 (USD MILLION)
      • U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS
        • Table U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE , BY PRESCRIPTION SLEEP AIDS, 2013-2021 (USD MILLION)
        • Table U.S.: PRESCRIPTIONS SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
        • Table U.S.: NON- BENZODIAZEPINE SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
      • U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE
        • Table U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • KEY PLAYERS IN THE U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET
      • Table KEY PLAYERS IN THE U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET (2016)
    • TOP AVAILABLE MOBILE APPLICATIONS FOR INSOMNIA
      • Table TOP AVAILABLE MOBILE APPLICATIONS FOR INSOMNIA (2016)
    • CORPORATE STRATEGIES FOLLOWED WITHIN U.S. INSOMNIA MARKET
    • COMPETITIVE SITUATIONS AND TRENDS
      • PRODUCT LAUNCHES & APPROVALS
        • Table PRODUCT LAUNCHES AND APPROVALS, 2013 -2016
      • COLLABORATIONS, AGREEMENTS AND PARTNERSHIPS
        • Table COLLABORATIONS, AGREEMENTS AND PARTNERSHIPS 2013-2016
      • ACQUISITIONS
        • Table ACQUISITIONS, 2013-2016
  • COMPANY PROFILES
    • SUNOVION PHARMACEUTICALS INC. (U.S. SUBSIDIARY OF SUMITOMO DAINIPPON PHARMA CO., LTD.)
    • BUSINESS OVERVIEW
      • EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF JAPANESE YEN TO USD)
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
    • SANOFI
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
    • PFIZER, INC
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEWS
    • TAKEDA PHARMACEUTICAL COMPANY LTD.
      • BUSINESS OVERVIEW
      • EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF JAPANESE YEN TO USD)
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
    • MERCK & CO., INC.
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • MEDA CONSUMER HEALTHCARE INC.
      • BUSINESS OVERVIEW
      • EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF SWEDISH KRONA TO USD)
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • EISAI CO., LTD
      • BUSINESS OVERVIEW
      • EXCHANGE RATE (UTILIZED FOR THE CONVERSION JAPANESE YEN TO USD)
      • PRODUCTS OFFERED
      • MNM VIEW
    • PURDUE PHARMACEUTICALS L.P.
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
    • PERNIX THERAPEUTICS
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • MNM VIEW
    • VANDA PHARMACEUTICALS: COMPANY SNAPSHOT
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
  • APPENDIX
    • DISCUSSION GUIDE
    • RELATED REPORTS
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • MARKETSANDMARKETS KNOWLEDGE STORE: SNAPSHOT
    • INTRODUCING RT: REAL TIME MARKET INTELLIGENCE
    • AUTHORS DETAILS
    • DISCLAIMER

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report